Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Cost-effectiveness of novel first-line treatment regimens for tuberculosis.

Owens JP, Fofana MO, Dowdy DW.

Int J Tuberc Lung Dis. 2013 May;17(5):590-6. doi: 10.5588/ijtld.12.0776.

2.

The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.

Knight GM, Gomez GB, Dodd PJ, Dowdy D, Zwerling A, Wells WA, Cobelens F, Vassall A, White RG.

PLoS One. 2015 Dec 30;10(12):e0145796. doi: 10.1371/journal.pone.0145796. eCollection 2015.

3.

A simplified cost-effectiveness model to guide decision-making for shortened anti-tuberculosis treatment regimens.

Zwerling A, Gomez GB, Pennington J, Cobelens F, Vassall A, Dowdy DW.

Int J Tuberc Lung Dis. 2016 Feb;20(2):257-60. doi: 10.5588/ijtld.15.0415.

PMID:
26792481
4.

Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.

Gomez GB, Dowdy DW, Bastos ML, Zwerling A, Sweeney S, Foster N, Trajman A, Islam MA, Kapiga S, Sinanovic E, Knight GM, White RG, Wells WA, Cobelens FG, Vassall A.

BMC Infect Dis. 2016 Dec 1;16(1):726.

5.

Cost-effectiveness of treating multidrug-resistant tuberculosis.

Resch SC, Salomon JA, Murray M, Weinstein MC.

PLoS Med. 2006 Jul;3(7):e241.

6.

Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.

Diel R, Hittel N, Schaberg T.

Respir Med. 2015 May;109(5):632-41. doi: 10.1016/j.rmed.2015.01.017. Epub 2015 Feb 4.

7.

Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.

Azadi M, Bishai DM, Dowdy DW, Moulton LH, Cavalcante S, Saraceni V, Pacheco AG, Cohn S, Chaisson RE, Durovni B, Golub JE.

Int J Tuberc Lung Dis. 2014 Dec;18(12):1443-8. doi: 10.5588/ijtld.14.0108.

8.

Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.

Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, Jackson JB.

Lancet. 1999 Sep 4;354(9181):803-9.

PMID:
10485721
9.

Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults.

Sun D, Dorman S, Shah M, Manabe YC, Moodley VM, Nicol MP, Dowdy DW.

Int J Tuberc Lung Dis. 2013 Apr;17(4):552-8. doi: 10.5588/ijtld.12.0627.

10.

Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis.

Dowdy DW, O'Brien MA, Bishai D.

Int J Tuberc Lung Dis. 2008 Sep;12(9):1021-9.

PMID:
18713499
11.

A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis.

Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR.

Chest. 1997 Jul;112(1):63-70.

PMID:
9228359
12.

Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.

Lu X, Smare C, Kambili C, El Khoury AC, Wolfson LJ.

BMC Health Serv Res. 2017 Jan 26;17(1):87. doi: 10.1186/s12913-016-1931-3.

13.

Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.

Esfahani K, Aspler A, Menzies D, Schwartzman K.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1340-6. doi: 10.5588/ijtld.10.0575.

PMID:
22283892
14.

Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens.

Gospodarevskaya E, Tulloch O, Bunga C, Ferdous S, Jonas A, Islam S, Rahman M, Hussain MA, Haque MN, Egwaga S, Gardiner E, PrayGod G, Islam MA, Mann GH, Wells WA, Squire SB.

Int J Tuberc Lung Dis. 2014 Jul;18(7):810-7. doi: 10.5588/ijtld.13.0391.

PMID:
24902557
15.

Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.

Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, Knerer G.

PLoS One. 2015 Mar 20;10(3):e0120763. doi: 10.1371/journal.pone.0120763. eCollection 2015.

16.

Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis.

Dowdy DW, Steingart KR, Pai M.

PLoS Med. 2011 Aug;8(8):e1001074. doi: 10.1371/journal.pmed.1001074. Epub 2011 Aug 9.

17.

Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults.

Dowdy DW, Lourenço MC, Cavalcante SC, Saraceni V, King B, Golub JE, Bishai D, Durovni B, Chaisson RE, Dorman SE.

PLoS One. 2008;3(12):e4057. doi: 10.1371/journal.pone.0004057. Epub 2008 Dec 29.

18.
19.
20.

Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.

Günther G, Gomez GB, Lange C, Rupert S, van Leth F; TBNET.

Eur Respir J. 2015 Apr;45(4):1081-8. doi: 10.1183/09031936.00124614. Epub 2014 Nov 13.

Supplemental Content

Support Center